Concurrent detection of sexual dysfunction and cardiovascular risk
|
|
Dr. Jacques Buvat |
Since 20 years, the prevalence of vascular risks factors (VRF) has been repeatedly reported to be increased in men consulting for Erectile Dysfunction (ED). VRF are independent risk factors for ED. According to calculations based on Framingham risk algorithms, due to its significant association with VRF ED should be an indicator for increased risk of Coronary Artery Disease (CAD), Myocardial Infarction (MI) and stroke (Relative Risks x 1,4 to 3).
While the CAD prevalence assessed with the treadmill test is not clearly increased in ED patients (14%), the ED prevalence is high in CAD patients (57%), suggesting that ED precedes CAD, and could be considered as a “sentinel” which could be used for screening for vascular disease, and taking preventive action against serious cardiovascular events (CVE); Most retrospective epidemiologic studies support this hypothesis by reporting high ED prevalence in men diagnosed with CAD documented by angiography (58%), silent ischemia in diabetic patients (34% vs 4% in diabetics without ischemia), MI (67%, mean interval of 38 months since the first ED symptoms), carotid or popliteal atherosclerosis (50%). However only 2 of the 4 prospective longitudinal studies reported to date (Thompson 2005, Schouten 2006) found that ED was a significant marker of incident cardiovascular disease (CVD) at the level of the general population (RR of CVE about 1,5). In an analysis of the MMAS study Araujo found a predictive value only for stroke in smokers (RR 2.95). Lastly the Frantzen data suggest that while ED could be seen as a marker for CVD before 1998 it was clearly not afterwards. The discrepancy in the prospective studies’ conclusions could result from the variable proportion of non vascular ED in the overall populations. Some pilot stud
Conflict of Interest: None disclosed Financial Support/Funding: None disclosed Recorded: Sydney, Australia, April 2007
|
Jacques Buvat
other talks by the speaker
|

Dr. Jacques Buvat
|
Dr. Jacques Buvat has been the director of the Centre d'Etude et de Traitement de la Pathologie de l'Appareil Reproducteur et de la Psychosomatique (CETPARP) in Lille, France since 1974. The center's research focuses on sexual dysfunctions, especially erectile dysfunction, infertility and in vitro fertilization, and endocrinology in gynecology and andrology.
Dr. Buvat is a member of editorial boards for the International Journal of Impotence Research, Archivio Italiano Nephrologia And rologia, Andrologie and Gynécologie Obstétrique Fertilité. He is also the chief editor of bulletins for the International Society for Sexual and Impotence Research and the French Société de Médecine de la Reproduction.
Active in the International Society for Sexual and Impotence Research since 1985, Dr. Buvat is currently the president-elect after having been secretary general and treasurer from 1996 to 2000. From 1991 to 1993, Dr. Buvat served as president of the French Speaking Society of Andrology and also directed the series "Progress In Andrology." He is a member of numerous professional societies, including the European Society for Impotence Research and has written more than 300 scientific papers or chapters in books.
Dr. Buvat is also the president of the Association pour l'Etude et le Traitement de la Pathologie de l'Appareil Reproducteur et de la Psychomatique, and of the Association pour le Développement de l'Information et de la Recherche sur la Sexualité (ADIRS), a non profit organisation dedicated to informing the public on sexuality and sexual problems. ADIRS is the French chapter of the European Sexual Dysfunction Alliance (ESDA).
|

Navigation
......................................
......................................
......................................
|
Help
......................................
......................................
......................................
|
Audio Visual Archives
......................................
......................................
......................................
|
Useful
......................................
......................................
......................................
|
|
|
|